GSK
@gsk.bsky.social
We are uniting science, technology and talent to get ahead of disease together.
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration.
Learn more: gsk.to/4qnf6Pd
Learn more: gsk.to/4qnf6Pd
February 10, 2026 at 7:05 AM
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration.
Learn more: gsk.to/4qnf6Pd
Learn more: gsk.to/4qnf6Pd
Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.
February 6, 2026 at 11:12 AM
Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.
#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD).
Learn more here: gsk.to/3O0TpXN
Learn more here: gsk.to/3O0TpXN
February 6, 2026 at 7:03 AM
#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD).
Learn more here: gsk.to/3O0TpXN
Learn more here: gsk.to/3O0TpXN
Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks.
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
February 4, 2026 at 7:40 AM
Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks.
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
Hear more from our CEO Luke Miels ⤵️
More information for media and investors: gsk.to/4r7A5qv $GSK #earnings
Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs
January 30, 2026 at 10:04 AM
Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC).
Learn more: gsk.to/49XpQhi
Learn more: gsk.to/49XpQhi
January 26, 2026 at 7:10 AM
#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC).
Learn more: gsk.to/49XpQhi
Learn more: gsk.to/49XpQhi
#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma.
Learn more here: gsk.to/4pQb3e1
Learn more here: gsk.to/4pQb3e1
January 23, 2026 at 7:05 AM
#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma.
Learn more here: gsk.to/4pQb3e1
Learn more here: gsk.to/4pQb3e1
January 20, 2026 at 7:15 AM
That's a wrap on #JPM2026!
We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
Check out our highlights ⤵️
#AheadTogether
We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
Check out our highlights ⤵️
#AheadTogether
January 16, 2026 at 2:03 PM
That's a wrap on #JPM2026!
We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
Check out our highlights ⤵️
#AheadTogether
We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together.
Check out our highlights ⤵️
#AheadTogether
Innovation starts when we stop to listen.
Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives.
🎥 Hear from the people who drive our purpose.
#AheadTogether #JPM2026 #JPM26
Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives.
🎥 Hear from the people who drive our purpose.
#AheadTogether #JPM2026 #JPM26
January 14, 2026 at 2:00 PM
Innovation starts when we stop to listen.
Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives.
🎥 Hear from the people who drive our purpose.
#AheadTogether #JPM2026 #JPM26
Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives.
🎥 Hear from the people who drive our purpose.
#AheadTogether #JPM2026 #JPM26
Heading to #JPM2026?
We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients.
See you there!
🔗 gsk.to/4buPbkT
We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients.
See you there!
🔗 gsk.to/4buPbkT
January 12, 2026 at 1:00 PM
Heading to #JPM2026?
We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients.
See you there!
🔗 gsk.to/4buPbkT
We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients.
See you there!
🔗 gsk.to/4buPbkT
#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines.
👉 Learn more: gsk.to/3LvBgAu
👉 Learn more: gsk.to/3LvBgAu
January 7, 2026 at 8:00 AM
#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines.
👉 Learn more: gsk.to/3LvBgAu
👉 Learn more: gsk.to/3LvBgAu
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB).
This marks an important step towards addressing the global burden of CHB.
Learn more: gsk.to/49HDLZM
This marks an important step towards addressing the global burden of CHB.
Learn more: gsk.to/49HDLZM
January 7, 2026 at 7:13 AM
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB).
This marks an important step towards addressing the global burden of CHB.
Learn more: gsk.to/49HDLZM
This marks an important step towards addressing the global burden of CHB.
Learn more: gsk.to/49HDLZM
#News for #investors and #media:
A new therapy for two respiratory diseases has received approval from Japan’s health authority.
Learn more here: gsk.to/3Lm8ZfI
A new therapy for two respiratory diseases has received approval from Japan’s health authority.
Learn more here: gsk.to/3Lm8ZfI
January 6, 2026 at 7:04 AM
#News for #investors and #media:
A new therapy for two respiratory diseases has received approval from Japan’s health authority.
Learn more here: gsk.to/3Lm8ZfI
A new therapy for two respiratory diseases has received approval from Japan’s health authority.
Learn more here: gsk.to/3Lm8ZfI
#News for #investors and #media:
We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease.
Learn more here: gsk.to/4jqC3PO
We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease.
Learn more here: gsk.to/4jqC3PO
January 5, 2026 at 7:06 AM
#News for #investors and #media:
We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease.
Learn more here: gsk.to/4jqC3PO
We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease.
Learn more here: gsk.to/4jqC3PO
Happy New Year from all of us! 🎉
As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together.
What are you looking forward to achieving in 2026?
As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together.
What are you looking forward to achieving in 2026?
January 1, 2026 at 10:00 AM
Happy New Year from all of us! 🎉
As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together.
What are you looking forward to achieving in 2026?
As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together.
What are you looking forward to achieving in 2026?
Season’s greetings from us at GSK to you! 🎄
May your day be filled with peace, happiness and special moments shared with those closest to you ✨
May your day be filled with peace, happiness and special moments shared with those closest to you ✨
December 25, 2025 at 10:00 AM
Season’s greetings from us at GSK to you! 🎄
May your day be filled with peace, happiness and special moments shared with those closest to you ✨
May your day be filled with peace, happiness and special moments shared with those closest to you ✨
From our network to yours, we’re wishing you a happy holiday season from across the globe!
Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇
Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇
December 24, 2025 at 10:00 AM
From our network to yours, we’re wishing you a happy holiday season from across the globe!
Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇
Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇
A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA).
For more information, visit: gsk.to/3KOUZLg
For more information, visit: gsk.to/3KOUZLg
December 16, 2025 at 11:03 PM
A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA).
For more information, visit: gsk.to/3KOUZLg
For more information, visit: gsk.to/3KOUZLg
We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers.
Watch to see how our team engaged at this year’s meeting! 🎥 🩸
Watch to see how our team engaged at this year’s meeting! 🎥 🩸
December 16, 2025 at 3:00 PM
We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers.
Watch to see how our team engaged at this year’s meeting! 🎥 🩸
Watch to see how our team engaged at this year’s meeting! 🎥 🩸
#News for #Media and #Investors:
Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases.
For more information, visit: www.gsk.com/en-gb/
Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases.
For more information, visit: www.gsk.com/en-gb/
December 15, 2025 at 9:10 PM
#News for #Media and #Investors:
Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases.
For more information, visit: www.gsk.com/en-gb/
Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases.
For more information, visit: www.gsk.com/en-gb/
At The Washington Post Live Post Next: The Future of Cancer event, Hesham Abdullah, Global Head of Oncology R&D shared what’s inspiring our vision to advance innovative research so those living with cancer can do more of what they love with those they care about most.
Watch the video bit.ly/4qcE6ZT
Watch the video bit.ly/4qcE6ZT
December 15, 2025 at 3:00 PM
At The Washington Post Live Post Next: The Future of Cancer event, Hesham Abdullah, Global Head of Oncology R&D shared what’s inspiring our vision to advance innovative research so those living with cancer can do more of what they love with those they care about most.
Watch the video bit.ly/4qcE6ZT
Watch the video bit.ly/4qcE6ZT
We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas.
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
December 13, 2025 at 10:00 AM
We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas.
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW
#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions.
Learn more: gsk.to/48MZ1M2
Learn more: gsk.to/48MZ1M2
December 12, 2025 at 2:08 PM
#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions.
Learn more: gsk.to/48MZ1M2
Learn more: gsk.to/48MZ1M2
#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines.
Access our website here: gsk.to/4aLrWTg
Access our website here: gsk.to/4aLrWTg
December 12, 2025 at 7:08 AM
#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines.
Access our website here: gsk.to/4aLrWTg
Access our website here: gsk.to/4aLrWTg